MRC International Partnership Survey 2020

This survey will be open until Sunday 21 June 2020 and must be completed on SurveyMonkey here.

Introduction

The MRC is planning our approach to international partnerships for the next 5 years.

In order to help us develop our strategy, we would appreciate input from our key UK stakeholders through the completion of this International Partnership Survey 2020. This is your opportunity to shape our future international partnership activities and funding calls, and we would like to hear about your current international activities, your future international ambitions, and the support that you would like to see from the MRC. We would also like to hear your thoughts on opportunities to collaborate with our UKRI sister Councils.

We understand this may be a difficult time to complete this survey due to covid-19. If you are able to respond, we would be very grateful if you could complete this survey by Sunday 21 June 2020 to make sure that we can use your valuable input to shape our future work.

Notes for completing the survey

Practical tips: The survey must be completed on SurveyMonkey here. However, for reference a PDF and word version of the survey are available here. The survey has up to 20 questions, and we envisage that it will take you about 15-25 mins to complete. We would recommend completing the survey in one go, however it should be possible to resume the survey as long as you use the same browser and device. It is best to use a computer, but you can use any device (i.e. phone, tablet). Please click on the ‘done’ button at the end of the survey to submit your full response to the MRC.

Covid-19: We understand that current covid-19 restrictions will likely have a significant impact on your research activities, both national and international, and this will be fully considered in our future planning. However, when completing this survey please consider your international ambitions in the longer term (~5 years) and assume a ‘business as usual’ approach as it is too early to provide a meaningful response to the impact of the coronavirus.

Brexit: We acknowledge that there is considerable uncertainty with regards to the future formal relationship of the UK to the EU Framework Programmes since the UK left the European Union, and the potential impact of this on UK research. Please let us know about your international ambitions in the fullest sense, regardless of the current source of funding. If you find particular funding mechanisms useful, we would like to hear about them, irrespective of funding source.

General

• We welcome responses from researchers who are Principal Investigators (PIs)/Co-Investigators (Co-Is)/Fellows only and who are based at/employed by UK organisations that are eligible for MRC funding (irrespective of current funding source). PIs/Co-Is/Fellows based at the MRC Units in The Gambia and Uganda are welcome to complete the survey. Senior research managers/facilitators at UK organisations eligible for MRC funding are also welcome to complete the survey.

• Anonymity of responses: you will have the option to add your name at the end of the survey, but you can fill in the survey anonymously if you prefer.
• All questions relate to ALL international (including EU) research and innovation collaborations that are within the MRC's remit irrespective of whether the funding comes from the MRC or another funder. Detailed information on MRC remit is available on the MRC website.
• Please also answer all questions on future opportunities based on scientific opportunity rather than expected availability of funding.
• Questions requiring an answer are marked with an asterisks (*)
• If you have questions about the survey, please contact internationalsurvey@mrc.ukri.org.

Section 1: About you

1. Please confirm that you meet the following criteria in order to complete the survey:
   You are based at/employed by a UK organisation eligible for MRC funding (irrespective of your current funding source) AND you are [Please select one option, answer required]
   a. a biomedical/health Principal Investigator (PI), Co-Investigator (Co-I) or Fellow
   b. a senior research manager/facilitator
   c. neither of the above (Please note that selecting this option means that you will not be able to complete the full survey)

2. Name of your institution [Answer required]
   [Dropdown list with option for ‘other’, please specify, 200 characters max incl. spaces]
   Tips:
   - Most MRC institutes/units/centres/partnerships are listed under M starting with 'MRC'.
   - For NHS Trusts, Hospitals, Boards, Primary Care Trusts and GP Practices please select 'National Health Service'.

3. Please tick all funding sources you have received in the last ten years [Please select all that apply, answer required]
   a. MRC funding
   b. Other UKRI funding
   c. Charity funding (from any country)
   d. EU funding
   e. Other international funding
   f. None of the above

Section 2: Current international collaborations

4. Overall, how important is international collaboration for your research? [Please select one option, answer required]
   a. Extremely important
   b. Very important
   c. Somewhat important
   d. Not so important
   e. Not at all important
   f. Not sure
5. What percentage of your current research and innovation activities involve international partners? [Please select one option, answer required] [Dropdown list: 0-25%, 26-50%, 51-75%, 76-100%]

6. How important are the following motivations for international collaboration? You may need to scroll right (on a tablet) to see all options. [Answer required]
   (Radio buttons - select one answer, compulsory: Extremely important, Very important, Somewhat important, Not so important, Not at all important, Not sure)
   a. Availability of funding
   b. Access to research settings/study subjects (patients, cohorts etc) not found in the UK
   c. Access to expertise not found in the UK
   d. Access to world-class expertise
   e. Access to infrastructures not found in the UK
   f. Enhance reputation of institution
   g. Enhance commercial impact of research
   h. Enhance policy impact of research
   i. Building capacity overseas
   j. Research of primary relevance outside the UK/to partner country

   Other, please specify [Optional, 400 characters max incl. spaces]
   [TEXT BOX, optional, 400 characters max incl. spaces]

7. How significant are the following barriers to limiting international collaboration? You may need to scroll right (on a tablet) to see all options. [Answer required]
   (Radio buttons - select one answer, compulsory: Extremely significant, Very significant, Somewhat significant, Not so significant, Not at all significant, Not sure)
   a. Lack of funding for UK researchers to participate in collaborations with international partners
   b. Lack of funding for international partners to participate in collaborations with UK researchers
   c. Lack of awareness of current funding opportunities for international collaboration
   d. Lack of time
   e. Funding timelines inadequate to conduct studies (e.g. grants too short)
   f. Risk that a proposed joint project will be approved in one country but not in another (‘double jeopardy’)
   g. Difficulties in identifying suitable international partners
   h. Differences in language and/or culture
   i. Differences in law/regulation/ethics e.g. transfer of materials, data access, intellectual property or ethical issues
   j. Difficulties in coordinating research activities across long distances and time zones
   k. Collaboration fatigue
   l. Practical difficulties e.g. visas, health insurance, family considerations

   Other, please specify [Optional, 800 characters max incl. spaces]
   [TEXT BOX, optional, 800 characters max incl. spaces]
8. Over the last 5 years, what are the main sources of funding that have supported your international collaboration(s)? [Please select all that apply, answer required]
   a. MRC responsive mode funding (grants and fellowships)
   b. MRC Global Health Funding (e.g. MRC/DFID African Research Leader scheme, Health Systems Research Initiative (HSRI), Joint Global Health Trials)
   c. Global Challenges Research Fund (GCRF)
   d. MRC Newton Fund
   e. MRC Fund for International Collaboration (FIC)
   f. Other UKRI funding calls
   g. European Union e.g. Horizon 2020 (including ERC, MSCA), IMI
   h. Learned societies and academies e.g. the Royal Society and the British Academy
   i. Charities/non-profit organisations e.g. the Wellcome Trust, CRUK, Bill & Melinda Gates Foundation, Chan Zuckerberg Initiative
   j. UK government departments e.g. DHSC, DfID
   k. Internal institution funding
   l. US National Institutes of Health (NIH)
   m. None

Other UK or International sources of funding, please specify [Optional, 400 characters max incl. spaces]

[TEXT BOX, optional, 400 characters max incl. spaces]

Section 3: Future international collaborations

Please answer all questions in this section based on scientific opportunity rather than availability of funding.

9. Over the next 5 years do you anticipate that your level of international collaboration will:
   [Please select one option, answer required]
   a) increase       b) remain at current level
   c) decrease       d) not sure

10. If you answered (a) or (b) to the previous question: over the next five years do you anticipate:
    [Please select all that apply, optional]
    a. Strengthening and deepening existing collaborations
    b. Developing new collaborations in countries with existing collaborations (i.e. working with different collaborators from the same country)
    c. Developing new collaborations in countries with no/very limited existing collaborations
    d. None of the above

Other, please specify [Optional, 400 characters max incl. spaces]

[TEXT BOX, optional, 400 characters max incl. spaces]
Section 4: Priority countries

Please answer all questions in this section based on scientific opportunity rather than availability of funding.

11. In priority order, please provide details of the top countries (up to 10) worldwide that you would like to collaborate with over the next 5 years (including new and existing collaborations) irrespective of funding source.

You may need to scroll right (on a mobile or a tablet) to see all three drop-down list questions.

[Please specify at least one country if possible].

Country 1 (Highest Priority)

<table>
<thead>
<tr>
<th>‘Country’</th>
<th>‘Status of collaboration’</th>
<th>‘MRC Board remit’</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dropdown list [Answer required]</td>
<td>Dropdown list [Answer required]</td>
<td>Dropdown list [Answer required]</td>
</tr>
<tr>
<td>• None</td>
<td>• Currently collaborate</td>
<td>• Applied Global Health</td>
</tr>
<tr>
<td>• Dropdown list of all countries worldwide (please see Annex 1 for a full list)</td>
<td>• Future collaboration</td>
<td>• Infections &amp; Immunity</td>
</tr>
<tr>
<td></td>
<td>• Current &amp; future</td>
<td>• Neurosciences &amp; Mental Health</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Molecular &amp; Cellular Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Population &amp; Systems Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Not sure</td>
</tr>
</tbody>
</table>

Country 1 - comments on scientific opportunity

Please provide brief details of collaboration plans and opportunities (e.g. highlight specific scientific strengths/opportunities such as ‘cancer’, ‘genomics’, ‘precision medicine’).

[Optional but please do include brief scientific areas if possible, 2000 characters max incl. spaces]

[TEXT BOX, optional, 2000 characters max incl. spaces]

Country 1 - comments on potential MRC support

Is this a country where you see significant scientific opportunities but have not been able to maximise engagement? If so, then please state briefly which (if any) kind of MRC support would be beneficial. [Optional, 2000 characters max incl. spaces]

[TEXT BOX, optional, 2000 characters max incl. spaces]

Option to add priority countries 2-10 [Optional]

For each country the dropdown lists, and comments box format are the same as above.
Section 5: MRC support for international collaboration

12. Overall, what do you think of the current level of MRC support for international collaboration? [Please select one option, answer required]
   a) Too little    b) About right    c) Too much    d) Not sure

Comments [Optional, 400 characters max incl. spaces]
[TEXT BOX, optional, 400 characters max incl. spaces]

13. How important would future MRC support/funding for the following activities be for you to realise your international ambitions? You may need to scroll right (on a tablet) to see all options. [Answer required]
   (Radio buttons - select one answer, compulsory: Extremely important, Very important, Somewhat important, Not so important, Not at all important, Not sure)
   a. MRC-led incoming and outgoing delegation visits to network and/or scope future research opportunities
   b. Travel/research scoping grants for individual researchers/research groups
   c. Funding for workshops led by individual researchers/research groups
   d. MRC-led support to identify future partners (e.g. online databases)
   e. Collaborative secondments and exchanges
   f. Long term outgoing placements abroad
   g. Long term incoming placements into UK
   h. Full scale collaborative research projects
   i. Institute to institute collaboration
   j. Innovation/Knowledge exchange activities

Other, please specify [Optional, 400 characters max incl. spaces]
[TEXT BOX, optional, 400 characters max incl. spaces]

14. In your research field, how important would future MRC international support be for the following career stages/specialisms? You may need to scroll right (on a tablet) to see all options. [Answer required]
   (Radio buttons - select one answer, compulsory: Extremely important, Very important, Somewhat important, Not so important, Not at all important, Not sure)
   a. Pre-doctoral researcher (e.g. PhD or Masters student)
   b. Post-doc researcher (e.g. employed on someone else’s grant)
   c. Early career independent researcher (PI on first independent funding)
   d. Established independent researcher (PI on several awards)
   e. Research technology specialist
   f. Research manager/support (e.g. project manager, research facilitator)
   g. All/any career stages

Other, please specify [Optional, 800 characters max incl. spaces]
[TEXT BOX, optional, 800 characters max incl. spaces]
15. How important is funding to support activities at the following levels? **You may need to scroll right (on a tablet) to see all options.** [Answer required]

(Radio buttons - select one answer, compulsory: Extremely important, Very important, Somewhat important, Not so important, Not at all important, Not sure)

a) Bilateral collaboration (between researchers in the UK and 1 other country)
b) Regional multilateral collaboration (between researchers in the UK and researchers from 2 or more countries within a geographical region, for example the EU or South East Asia)
c) Global multilateral collaboration (between researchers in the UK and multiple other countries not necessarily in the same geographical region)

Comment: [Optional, 2000 characters max incl. spaces]

16. Please provide details of any international interdisciplinary opportunities (up to 3 opportunities) that you feel could benefit from cross-UKRI international support. **You may need to scroll right (on a tablet) to see all options.** [Answer optional]

**Opportunity 1:** [Please tick all councils that apply for your first opportunity]

- AHRC (Arts and Humanities)
- BBSRC (Biotechnology and Biological Sciences)
- ESRC (Economic and Social)
- EPSRC (Engineering and Physical Sciences)
- Innovate UK
- NERC (Natural Environment)
- Research England
- STFC (Science and Technology Facilities)
- All (UKRI-wide)

**Opportunity 1 - Comments on the scientific opportunity**
Please provide details of the scientific opportunity, and the support you would wish to see (e.g. highlight specific scientific strengths/opportunities such as 'cancer', 'genomics', 'precision medicine'). [Optional but please do include brief scientific areas if possible, 2000 characters max incl. spaces]

**Opportunity 1 - Please specify up to three countries that you would like to work with in this research area** [Optional, but please specify at least one country if possible] **You may need to scroll right to see all three drop-down lists.**

**Countries 1-3 Dropdown lists** [Optional]
- None
- Dropdown list of all countries worldwide (please see Annex 1 for a full list)
**Opportunity 1** – Please specify which MRC Board Remit(s) your suggested opportunity would fit under, if known. [Optional]

(Check-box options: Applied Global Health / Infections & Immunity / Neurosciences & Mental Health / Molecular & Cellular Medicine / Population & Systems Medicine / None / Not sure)

**Option to add up to 2 more opportunities**
For each opportunity the question format is the same as above.

---

**Section 6: Other comments**

17. Do you have any other comments on MRC support for international collaboration not addressed previously in this questionnaire? [Answer required]
   a) No
   b) Yes. If so, then please provide details [Optional, 2000 characters max incl. spaces]

**Section 7: Contact details and data protection information**

You can fill in the survey anonymously or you can choose to provide your contact details below. You may also choose if/when you would like to give us permission to contact you.

18. **Your name and department details** [Optional, please see below for Data Protection information]

<table>
<thead>
<tr>
<th>Title (Optional)</th>
</tr>
</thead>
<tbody>
<tr>
<td>First name (Optional)</td>
</tr>
<tr>
<td>Surname (Optional)</td>
</tr>
<tr>
<td>Department (Optional)</td>
</tr>
</tbody>
</table>

**Data protection information**: All personal data provided to UK Research and Innovation in connection to this survey will be processed in accordance with current UK data protection legislation. Further background information on UK Research and Innovation support for international funding can be found on the MRC International website. Further information on how we use personal data, and how you can exercise your rights as a data subject, can be found in the UK Research and Innovation Privacy Notice (https://www.ukri.org/privacy-notice).
19. Are you a registered user of the UK Research and Innovation (UKRI) Joint Electronic Submissions (Je-S) system? [Answer required]

Tip: All MRC/UKRI PIs, Co-Is and Fellows do have a registered account on Je-S, so should tick 'Yes'.

   a) Yes (if you select this option you will go to question 20 version for Je-S users below)
   b) No (if you select this option you will go to question 20 version for non Je-S users below)

Qu 20 – version for Je-S users

Contact permissions (Je-S users only):
In the Je-S standard terms and conditions ‘Section 3.2 Use of your personal information’ includes that personal data may be used in relation to Research Council policy and strategy studies.

Do you also give the MRC additional consent to contact you to provide information related to topics/countries that you have expressed interest in (for example to invite you to future relevant events)? [Answer required]

   a) No
   b) Yes. If so, then please provide your email address so that we can contact you.
      Please take care to double-check that your email address is correct and typo free, thank you. [Answer required]

Your email address

Withdrawing consent: You can withdraw your additional consent at any time in the future if you wish by emailing international@mrc.ukri.org with the subject line ‘Withdraw consent – MRC International Partnerships Survey 2020 (Your name)’.

Data protection information: All personal data provided to UK Research and Innovation in connection to this survey will be processed in accordance with current UK data protection legislation. Further background information on UK Research and Innovation support for international funding can be found on the MRC International website. Further information on how we use personal data, and how you can exercise your rights as a data subject, can be found in the UK Research and Innovation Privacy Notice (https://www.ukri.org/privacy-notice).

Qu 20 – version for non Je-S users

Contact permissions (Non Je-S users only):
Please indicate below if you give the MRC permission to contact for you the following reasons. [Optional, please select all that apply]

   a) For queries related to your survey response (for example to seek clarification or to ask for further information about your replies, or to provide information about future events related to topics/countries that you have expressed interest in)
b) For engagement in future MRC policy and strategy studies (for example to receive invitations to participate in similar surveys on MRC international funding in future years)

If you have ticked (a) and/or (b) above please provide your email address below. Please take care to double-check that your email address is correct and typo free, thank you. [Optional]

Your email address

Withdrawing consent: You can withdraw your consent at any time in the future if you wish by emailing international@mrc.ukri.org with the subject line ‘Withdraw consent – MRC International Partnerships Survey 2020 (Your name)’.

Data protection information: All personal data provided to UK Research and Innovation in connection to this survey will be processed in accordance with current UK data protection legislation. Further background information on UK Research and Innovation support for international funding can be found on the MRC International website. Further information on how we use personal data, and how you can exercise your rights as a data subject, can be found in the UK Research and Innovation Privacy Notice (https://www.ukri.org/privacy-notice).

Section 8: Thank you

Thank you for taking the time to complete this survey.

Please click ‘done’ below (on SurveyMonkey) to submit your survey response.

If you wish, you may (using the same device and browser) come back and edit your response, and then resubmit your response (by pressing the Done button again).
### Annex 1: Dropdown list of all countries worldwide excluding the UK (for question 11)

<table>
<thead>
<tr>
<th>None</th>
<th>Djibouti</th>
<th>Libya</th>
<th>San Marino</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afghanistan</td>
<td>Dominica</td>
<td>Liechtenstein</td>
<td>Sao Tome and Principe</td>
</tr>
<tr>
<td>Albania</td>
<td>Dominican</td>
<td>Lithuania</td>
<td>Senegal</td>
</tr>
<tr>
<td>Algeria</td>
<td>Republic</td>
<td>Luxembourg</td>
<td>Saudi Arabia</td>
</tr>
<tr>
<td>Andorra</td>
<td>Ecuador</td>
<td>Madagascar</td>
<td></td>
</tr>
<tr>
<td>Angola</td>
<td>Egypt</td>
<td>Malawi</td>
<td>Serbia</td>
</tr>
<tr>
<td>Antigua and Barbuda</td>
<td>El Salvador</td>
<td>Malaysia</td>
<td>Seychelles</td>
</tr>
<tr>
<td>Barbuda</td>
<td>Equatorial Guinea</td>
<td>Maldives</td>
<td>Sierra Leone</td>
</tr>
<tr>
<td>Argentina</td>
<td>Eritrea</td>
<td>Mali</td>
<td>Singapore</td>
</tr>
<tr>
<td>Armenia</td>
<td>Estonia</td>
<td>Malta</td>
<td>Slovakia</td>
</tr>
<tr>
<td>Australia</td>
<td>Eswatini</td>
<td>Marshall Islands</td>
<td>Slovenia</td>
</tr>
<tr>
<td>Austria</td>
<td>Ethiopia</td>
<td>Mauritania</td>
<td></td>
</tr>
<tr>
<td>Azerbaijan</td>
<td>Federated States of</td>
<td>Mauritius</td>
<td>Somalia</td>
</tr>
<tr>
<td>Bahamas</td>
<td>Micronesia</td>
<td>Mexico</td>
<td>South Africa</td>
</tr>
<tr>
<td>Bahrain</td>
<td>Fiji</td>
<td>Moldova</td>
<td>South Korea</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>Finland</td>
<td>Monaco</td>
<td>South Sudan</td>
</tr>
<tr>
<td>Barbados</td>
<td>France</td>
<td>Mongolia</td>
<td>Spain</td>
</tr>
<tr>
<td>Belarus</td>
<td>Gabon</td>
<td>Montenegro</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td>Belgium</td>
<td>Gambia</td>
<td>Morocco</td>
<td>Sudan</td>
</tr>
<tr>
<td>Belize</td>
<td>Georgia</td>
<td>Mozambique</td>
<td>Suriname</td>
</tr>
<tr>
<td>Benin</td>
<td>Germany</td>
<td>Myanmar</td>
<td>Sweden</td>
</tr>
<tr>
<td>Bhutan</td>
<td>Ghana</td>
<td>Namibia</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Bolivia</td>
<td>Greece</td>
<td>Nauru</td>
<td>Syrian Arab</td>
</tr>
<tr>
<td>Bosnia and Herzegovina</td>
<td>Grenada</td>
<td>Nepal</td>
<td>Republic</td>
</tr>
<tr>
<td>Herzegovina</td>
<td>Guatemala</td>
<td>Netherlands</td>
<td>Tajikistan</td>
</tr>
<tr>
<td>Botswana</td>
<td>Guinea</td>
<td>New Zealand</td>
<td>Tanzania</td>
</tr>
<tr>
<td>Brazil</td>
<td>Guinea-Bissau</td>
<td>Nicaragua</td>
<td>Thailand</td>
</tr>
<tr>
<td>Brunei Darussalam</td>
<td>Guyana</td>
<td>Niger</td>
<td>Timor-Leste</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>Haiti</td>
<td>Nigeria</td>
<td>Togo</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>Honduras</td>
<td>North Korea</td>
<td>Tonga</td>
</tr>
<tr>
<td>Burundi</td>
<td>Hungary</td>
<td>North Macedonia</td>
<td>Trinidad and Tobago</td>
</tr>
<tr>
<td>Cambodia</td>
<td>Iceland</td>
<td>Norway</td>
<td>Tobago</td>
</tr>
<tr>
<td>Cameroon</td>
<td>India</td>
<td>Oman</td>
<td>Tunisia</td>
</tr>
<tr>
<td>Canada</td>
<td>Indonesia</td>
<td>Pakistan</td>
<td>Turkey</td>
</tr>
<tr>
<td>Cape Verde</td>
<td>Iran</td>
<td>Palau</td>
<td>Turkmenistan</td>
</tr>
<tr>
<td>Central African</td>
<td>Iraq</td>
<td>Panama</td>
<td>Tuvalu</td>
</tr>
<tr>
<td>Republic</td>
<td>Ireland</td>
<td>Papua New Guinea</td>
<td>Uganda</td>
</tr>
<tr>
<td>Chad</td>
<td>Israel</td>
<td>Paraguay</td>
<td>Ukraine</td>
</tr>
<tr>
<td>Chile</td>
<td>Italy</td>
<td>Peru</td>
<td>United Arab</td>
</tr>
<tr>
<td>China</td>
<td>Jamaica</td>
<td>Philippines</td>
<td>Emirates</td>
</tr>
<tr>
<td>Colombia</td>
<td>Japan</td>
<td>Poland</td>
<td>United States</td>
</tr>
<tr>
<td>Comoros</td>
<td>Jordan</td>
<td>Portugal</td>
<td>Uruguay</td>
</tr>
<tr>
<td>Congo</td>
<td>Kazakhstan</td>
<td>Qatar</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>Kenya</td>
<td>Romania</td>
<td>Vanuatu</td>
</tr>
<tr>
<td>Côte d’Ivoire</td>
<td>Kiribati</td>
<td>Russian Federation</td>
<td>Venezuela</td>
</tr>
<tr>
<td>Croatia</td>
<td>Kuwait</td>
<td>Rwanda</td>
<td>Viet Nam</td>
</tr>
<tr>
<td>Cuba</td>
<td>Kyrgyzstan</td>
<td>Saint Kitts and</td>
<td>Yemen</td>
</tr>
<tr>
<td>Cyprus</td>
<td>Laos</td>
<td>Nevis</td>
<td></td>
</tr>
<tr>
<td>Czech Republic</td>
<td>Latvia</td>
<td>Saint Lucia</td>
<td></td>
</tr>
<tr>
<td>Democratic Republic Congo</td>
<td>Lesotho</td>
<td>Saint Vincent and the Grenadines</td>
<td>Zimbabwe</td>
</tr>
<tr>
<td>Denmark</td>
<td>Liberia</td>
<td>Samoa</td>
<td></td>
</tr>
</tbody>
</table>